X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement is signed for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV).
Lead Product(s): MBP134
Therapeutic Area: Infections and Infectious Diseases Product Name: MBP134
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Mapp Biopharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 23, 2023
Details:
The agreement supports the development of molecules targeting acute myeloid leukemia, multiple myeloma, human papilloma virus (HPV) associated tumors, and additional human leukocyte antigens (HLAs) that have the potential to increase immunotherapy options for patients.
Lead Product(s): HLA IgG4 Fusion Proteins,T-cell Co-stimulatory Monoclonal Antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: NexImmune
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 08, 2022
Details:
Genolar, Generium’s biosimilar of omalizumab is third Selexis SUREtechnology Platform generated to reach market, is a recombinant humanized IgG1k monoclonal antibody biosimilar that binds to free human immunoglobulin E for the treatment of persistent atopic bronchial asthma.
Lead Product(s): Omalizumab
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Genolar
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Generium JSC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2022
Details:
Under the agreement, Hemogenyx will leverage Selexis’ proprietary SUREtechnology Platform™, a suite of cell line development tools and technologies that significantly reduces the time, effort, and costs associated with developing high-performance mammalian cell lines.
Lead Product(s): CDX bi-specific antibodies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Recipient: Hemogenyx Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 12, 2022
Details:
Under the agreements, Selexis will utilize its SUREtechnology Platform™ and KBI will leverage its advanced analytics, process, formulation and cGMP manufacturing for Immatics’ IMA402 program.
Lead Product(s): IMA402
Therapeutic Area: Oncology Product Name: IMA402
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 29, 2021
Details:
KBI will conduct manufacturing and validation in its existing facilities. AM-Pharma and KBI Biopharma began collaborating on the recAP program in 2011 when KBI performed initial process development and cGMP manufacturing for early clinical use.
Lead Product(s): Ilofotase Alfa
Therapeutic Area: Nephrology Product Name: recAP
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AM-Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 17, 2021
Details:
Under the terms of the agreement, Pandion will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance PT627 to human trials.
Lead Product(s): PT627
Therapeutic Area: Immunology Product Name: PT627
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Pandion Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 16, 2021
Details:
The agreement focuses to develop the cell line for BITR2101, BITT’s lead tumor necrosis factor receptor 2 (TNFR2) antagonist antibody for the treatment of cancers and infectious diseases.
Lead Product(s): BITR2101
Therapeutic Area: Oncology Product Name: BITR2101
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: BITT
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 09, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
